Abstract
Background: Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric myeloproliferative disease, but several newly diagnosed patients cannot tolerate hematopoietic stem cell transplantation (HSCT) at diagnosis. Aims: n the present study, we aimed to explore the short-term effect of decitabine in combination with low-dose chemotherapy on improving the condition of JMML patients before HSCT. Methods: A total of 10 JMML patients were enrolled in this retrospective analysis. All the patients were treated with decitabine supplemented with low-dose chemotherapy with a interval of 4 weeks, bridging to HSCT after three~four courses. Results: The median treatment course was three (one-five) cycles, and the response rate was 70.0% after one cycle and 71.4% after three cycles. The WBC and monocyte counts were significantly decreased after chemotherapy, and the spleen volume showed a decreasing tendency. The 12-month progression-free survival rate was 80.0±12.6%. Image:Summary/Conclusion: Decitabine in combination with low-dose chemotherapy was favorable in reducing tumor burden and improving the clinical status.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
